Teichmann A T, Cremer P, Wieland H, Kuhn W, Seidel D
Dept. of Gynaecology and Obstetrics, University of Göttingen, F.R.G.
Maturitas. 1988 May;10(1):27-33. doi: 10.1016/0378-5122(88)90128-4.
Three groups of patients with pelvic endometriosis were treated with medroxyprogesterone acetate (MPA) 50 mg/day (n = 10), lynestrenol (LYN) 10 mg/day (n = 25) and danazol (DAN) 600 mg/day (n = 25) respectively. Total cholesterol, triglycerides, alpha-lipoprotein, prebetalipoprotein, beta-lipoprotein cholesterol, high-density (HDL) and low-density (LDL) lipoprotein and apolipoprotein A1 and B concentrations were determined before treatment and after 3 and 6 mth of therapy. Whereas lipid, lipoprotein and apolipoprotein levels did not change in the MPA group, the patients on LYN and in particular those on DNA showed marked changes in lipoportein patterns. Alpha-lipoprotein, HDL and apolipoprotein A1 levels fell, while beta-lipoprotein, LDL and apolipoprotein concentrations rose, these changes being statistically significant. No alterations were seen in the serum levels of cholesterol, triglycerides or prebetalipoprotein cholesterol. In view of a possible relationship between high LDL and low HDL levels and a risk of accelerated coronary arteriosclerosis in women it was concluded that progestogen-induced alterations in lipoprotein patterns should be avoided as far as long-term treatment is concerned and where additional risk factors are present.
三组盆腔子宫内膜异位症患者分别接受醋酸甲羟孕酮（MPA）50毫克/天（n = 10）、炔诺醇（LYN）10毫克/天（n = 25）和达那唑（DAN）600毫克/天（n = 25）治疗。在治疗前以及治疗3个月和6个月后测定总胆固醇、甘油三酯、α-脂蛋白、前β-脂蛋白、β-脂蛋白胆固醇、高密度（HDL）和低密度（LDL）脂蛋白以及载脂蛋白A1和B的浓度。MPA组的脂质、脂蛋白和载脂蛋白水平未发生变化，而LYN组尤其是DAN组的患者脂蛋白模式出现了明显变化。α-脂蛋白、HDL和载脂蛋白A1水平下降，而β-脂蛋白、LDL和载脂蛋白浓度上升，这些变化具有统计学意义。血清胆固醇、甘油三酯或前β-脂蛋白胆固醇水平未见改变。鉴于女性中高LDL和低HDL水平与冠状动脉粥样硬化加速风险之间可能存在关联，得出的结论是，就长期治疗而言，以及在存在其他风险因素的情况下，应避免孕激素引起的脂蛋白模式改变。
